Table 3.

Changes in parameters measured by cardiac magnetic resonance after 12 months dapagliflozin treatment

Variable	Intention-to-treat analysis				Per-protocol analysis
	Dapagliflozin	Placebo	Differencea	P-Value	Dapagliflozin	Placebo	Differencea	P-Value
	(n = 32)	(n = 34)	(95% CI)		(n = 29)	(n = 33)	(95% CI)
Primary endpoint
Absolute LVM (g)	−3.95 ± 4.85	−1.13 ± 4.55	−2.82 (−5.13 to −0.51)	0.018	−4.36 ± 4.92	−1.17 ± 4.43	−3.2 (−5.62 to −0.77)	0.011
Secondary endpoints
LVMI BSA (g/m2)	−0.58 ± 2.29	−0.38 ± 1.79	−0.20 (−1.21 to 0.80)	0.691	−0.64 ± 2.40	−0.39 ± 1.81	−0.25 (−1.32 to 0.82)	0.644
LVMI Height (g/m)	−2.33 ± 2.87	−0.71 ± 2.68	−1.62 (−2.99 to −0.26)	0.021	−2.57 ± 2.91	−0.73 ± 2.72	−1.84 (−3.27 to −0.41)	0.013
LVMI Height1.7 (g/m1.7)	−1.61 ± 2.00	−0.51 ± 1.87	−1.09 (−2.05 to −0.15)	0.024	−1.78 ± 2.03	−0.52 ± 1.89	−1.25 (−2.25 to −0.25)	0.015
LVMI Height2.7 (g/m2.7)	−0.95 ± 1.20	−0.32 ± 1.12	−0.63 (−1.21 to −0.06)	0.031	−1.05 ± 1.22	−0.33 ± 1.14	−0.72 (−1.32 to−0.12)	0.020
EF (%)	1.45 ± 4.08	0.66 ± 3.76	0.79 (−1.14 to 2.72)	0.415	1.60 ± 4.26	0.68 ± 3.81	0.92 (−1.13 to 2.97)	0.372
EDV (mLs)	−0.15 ± 11.59	1.44 ± 10.62	−1.59 (−7.06 to 3.87)	0.562	−0.17 ± 12.20	1.48 ± 10.78	−1.65 (−7.49 to 4.18)	0.573
ESV (mLs)	−1.86 ± 4.83	−0.74 ± 4.81	−1.12 (−3.50 to 1.25)	0.348	−2.05 ± 5.04	−0.76 ± 4.89	−1.29 (−3.82 to 1.23)	0.310
SV (mLs)	1.71 ± 11.18	2.18 ± 10.45	−0.47 (−5.79 to 4.85)	0.860	1.88 ± 11.75	2.24 ± 10.60	−0.36 (−6.04 to 5.32)	0.900
Left atrial area (Cm2)b	−0.25 ± 3.38	0.00 ± 3.5	−1.20 (−2.82 to 0.42)	0.143	−0.5 ± 3.75	0.0 ± 3.5	−1.29 (−3.01 to 0.44)	0.088

P-values in bold indicate <0.05.

BSA, body surface area; EDV, end-diastolic volume; EF, ejection fraction; ESV; end-systolic volume; LVM, left ventricular mass; LVMI, left ventricular mass index; SV, stroke volume.

^aAbsolute mean difference between groups. All values expressed in mean ± SD unless stated.

^bMedian ± IQR.